Migration and proliferative effects of cancer-associated fibroblasts on lymphatic endothelial cells in malignant melanoma
| Project/Area Number |
18K16992
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56070:Plastic and reconstructive surgery-related
|
|---|
| Research Institution | Osaka Metropolitan University (2022)
Osaka City University (2018-2021) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 悪性黒色腫 / 癌関連線維芽細胞 / リンパ管新生 / リンパ管内皮細胞 |
|---|
| Outline of Final Research Achievements |
Our research focused on cancer-associated fibroblasts in the tumor microenvironment, which are deeply involved in cancer cell progression. Lymphangiogenesis is induced in cancer tissues, resulting in increase of lymphatic vessels in the tissues and causes lymph node metastasis. Malignant melanoma is prone to lymph node metastasis. Therefore, we evaluated the effect of cancer-associated fibroblasts on lymph node metastasis. The results suggest that cancer-associated fibroblasts affected by cancer cells promote proliferation of lymphatic endothelial cells. We attempted to find cytokines associated with this effect, but were unable to identify any substances that actually promote lymphatic endothelial cell proliferation.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究において、悪性黒色腫の腫瘍微小環境における癌関連線維芽細胞によってリンパ管内皮細胞の増殖が促進される可能性が考えられた。すなわちリンパ管新生、ひいてはリンパ節転移に影響を与えることが示唆される。しかし、それに影響を与えるサイトカインの同定には至らなかった。引き続きリンパ管新生に関与する物質を検索し、その阻害剤の開発が望まれる。
|
Report
(6 results)
Research Products
(2 results)
